Women’s Health at the Center of the 2025–2027 Global Public Affairs Agenda – ISTH
ISTH – International Society on Thrombosis and Haemostasis shared a post on LinkedIn:
“Today, the ISTH unveils its 2025–2027 global public affairs agenda, placing women’s health at the center of global policy and advocacy efforts.
From pregnancy-related thrombosis to postpartum hemorrhage and bleeding disorders that uniquely affect women, the ISTH is aligning scientific expertise with evidence-based policy to strengthen health systems worldwide.
With this upcoming International Womens Day in mind, we reaffirm our commitment to equitable care for women worldwide.
Women around the world continue to face profound health inequities:
- 2 billion women and girls lack social protection
- 63% give birth without maternity benefits
- Women are 50% more likely to be misdiagnosed after a heart attack
The science is ready.
The data is clear.
Now policy must follow.
Learn more about the ISTH’s global public affairs initiatives.”
Other posts about International Society on Thrombosis and Haemostasis .
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities
-
Apr 22, 2026, 14:10Alan Nurden: Pregnancy Challenges and Bleeding Risks in Inherited Platelet Disorders
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing
-
Apr 22, 2026, 11:47We Are Excited to Introduce You to the 11th Editor-in-Chief Dr. Bob Löwenberg – Blood Journals Portfolio
-
Apr 22, 2026, 11:35Congratulations to Donald Arnold for Being Recognized with The ISTH 2026 Harold R. Roberts Award
-
Apr 22, 2026, 11:27Prashasti Dahiya: Key Molecular Insights on Thromboinflammation and Angiogenesis in Pediatric Cancer
-
Apr 22, 2026, 11:17Jack Hadfield: Understanding the Immune and Genetic Basis of VITT Post-COVID Vaccines